Barriers and facilitators to mobile health and active surveillance use among older adults with skin disease.
active surveillance
ageing
dermatology
mobile health
older adults
telemedicine
Journal
Health expectations : an international journal of public participation in health care and health policy
ISSN: 1369-7625
Titre abrégé: Health Expect
Pays: England
ID NLM: 9815926
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
29
01
2021
received:
20
10
2020
accepted:
18
02
2021
pubmed:
1
7
2021
medline:
6
10
2021
entrez:
30
6
2021
Statut:
ppublish
Résumé
The COVID-19 pandemic has accelerated the adoption of telemedicine, including teledermatology. Monitoring skin lesions using teledermatology may become increasingly important for several skin diseases, including low-risk skin cancers. The purpose of this study was to describe the key factors that could serve as barriers or facilitators to skin disease monitoring using mobile health technology (mHealth) in older adults. Older adult dermatology patients 65 years or older and their caregivers who have seen a dermatologist in the last 18 months were interviewed and surveyed between December 2019 and July 2020. The purpose of these interviews was to better understand attitudes, beliefs and behaviours that could serve as barriers and facilitators to the use of mHealth and active surveillance to monitor low-risk skin cancers. A total of 33 interviews leading to 6022 unique excerpts yielded 8 factors, or themes, that could serve as barriers, facilitators or both to mHealth and active surveillance. We propose an integrated conceptual framework that highlights the interaction of these themes at both the patient and provider level, including care environment, support systems and personal values. These preliminary findings reveal factors influencing patient acceptance of active surveillance in dermatology, such as changes to the patient-provider interaction and alignment with personal values. These factors were also found to influence adoption of mHealth interventions. Given such overlap, it is essential to address barriers and facilitators from both domains when designing a new dermatology active surveillance approach with novel mHealth technology. The patients included in this study were participants during the data collection process. Members of the Stanford Healthcare and Denver Tech Dermatology health-care teams aided in the recruitment phase of the data collection process.
Sections du résumé
BACKGROUND
The COVID-19 pandemic has accelerated the adoption of telemedicine, including teledermatology. Monitoring skin lesions using teledermatology may become increasingly important for several skin diseases, including low-risk skin cancers. The purpose of this study was to describe the key factors that could serve as barriers or facilitators to skin disease monitoring using mobile health technology (mHealth) in older adults.
METHODS
Older adult dermatology patients 65 years or older and their caregivers who have seen a dermatologist in the last 18 months were interviewed and surveyed between December 2019 and July 2020. The purpose of these interviews was to better understand attitudes, beliefs and behaviours that could serve as barriers and facilitators to the use of mHealth and active surveillance to monitor low-risk skin cancers.
RESULTS
A total of 33 interviews leading to 6022 unique excerpts yielded 8 factors, or themes, that could serve as barriers, facilitators or both to mHealth and active surveillance. We propose an integrated conceptual framework that highlights the interaction of these themes at both the patient and provider level, including care environment, support systems and personal values.
DISCUSSION AND CONCLUSIONS
These preliminary findings reveal factors influencing patient acceptance of active surveillance in dermatology, such as changes to the patient-provider interaction and alignment with personal values. These factors were also found to influence adoption of mHealth interventions. Given such overlap, it is essential to address barriers and facilitators from both domains when designing a new dermatology active surveillance approach with novel mHealth technology.
PATIENT OR PUBLIC CONTRIBUTION
The patients included in this study were participants during the data collection process. Members of the Stanford Healthcare and Denver Tech Dermatology health-care teams aided in the recruitment phase of the data collection process.
Identifiants
pubmed: 34190397
doi: 10.1111/hex.13229
pmc: PMC8483196
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1582-1592Subventions
Organisme : NIAMS NIH HHS
ID : K24 AR075060
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG066980
Pays : United States
Organisme : NIH HHS
ID : R21AG066980
Pays : United States
Organisme : NIH HHS
ID : K24AR075060
Pays : United States
Informations de copyright
© 2021 The Authors. Health Expectations published by John Wiley & Sons Ltd.
Références
Eur Urol. 2018 Sep;74(3):261-280
pubmed: 29598981
Int J Med Inform. 2019 Apr;124:68-77
pubmed: 30784429
J Am Geriatr Soc. 2016 Aug;64(8):1610-5
pubmed: 27303932
J Med Internet Res. 2020 Jun 9;22(6):e19264
pubmed: 32463377
Transl Androl Urol. 2018 Feb;7(1):170-181
pubmed: 29594031
JAMA Intern Med. 2013 Jun 10;173(11):1006-12
pubmed: 23699934
Int J Med Inform. 2018 Jun;114:66-75
pubmed: 29673606
Stud Health Technol Inform. 2015;210:783-7
pubmed: 25991261
JAMA Dermatol. 2015 Oct;151(10):1081-6
pubmed: 25928283
Cancer Med. 2017 Oct;6(10):2410-2418
pubmed: 28925011
J Natl Med Assoc. 2011 Jun;103(6):468-78
pubmed: 21830629
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
JMIR Public Health Surveill. 2020 Apr 7;6(2):e18961
pubmed: 32250963
JBI Database System Rev Implement Rep. 2016 Feb;14(2):174-255
pubmed: 27536798
J Clin Nurs. 2016 Apr;25(7-8):1166-72
pubmed: 26786713
Health Expect. 2021 Oct;24(5):1582-1592
pubmed: 34190397
J Am Acad Dermatol. 2019 Jan;80(1):208-250
pubmed: 30392755
Arch Dermatol. 2012 Apr;148(4):473-7
pubmed: 22508870
JMIR Aging. 2018 Dec 04;1(2):e12178
pubmed: 31518257
Cancer Epidemiol Biomarkers Prev. 2016 Aug;25(8):1240-50
pubmed: 27257092
JAMA. 2014 Sep 10;312(10):997-8
pubmed: 25203077
Aging Dis. 2017 Oct 1;8(5):643-661
pubmed: 28966807
BMJ. 2012 Oct 02;345:e5909
pubmed: 23033409
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
N Engl J Med. 2017 Jul 20;377(3):203-206
pubmed: 28723330